vimarsana.com

Page 39 - ஓஹியோ நிலை பல்கலைக்கழகம் வெக்ஸ்னர் மருத்துவ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Healthy State Alliance Hosts COVID-19 For The Long Haul Symposium

April 9, 2021 COLUMBUS, Ohio – To further educate the health care community, Bon Secours Mercy Health and The Ohio State University Wexner Medical Center are hosting COVID-19 for the Long Haul, a continuing medical education event about how to care for patients in post-COVID recovery. The collaboration is a direct result of Healthy State Alliance, a strategic initiative between the two organizations to work together to improve community health.    The virtual event is April 10 from 8 a.m. to 11:30 a.m. with Gov. Mike DeWine providing opening remarks to the more than 1,100 health care workers from 19 states registered to attend.     Physicians from both organizations will speak on topics such as COVID-19 risk factors and symptoms, the role of exercise, therapy, pain management and nutrition as well as the community health impact and community resources available to assist with recovery. 

Rise of coronavirus variants will define the next phase of the pandemic in the US

. WASHINGTON  Variants of the coronavirus are increasingly defining the next phase of the pandemic in the United States, taking hold in ever-greater numbers and eliciting pleas for a change in strategy against the outbreak, according to government officials and experts tracking developments. The highly transmissible B.1.1.7 variant that originated in the United Kingdom now accounts for 27% of all cases in this country. It is the most common variant in the United States, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said Wednesday  a development that officials predicted months ago. Two other variants, which took root in South Africa and Brazil and also are more transmissible, are cropping up with increasing frequency in parts of the United States.

Vaccine Trial Results Vs Real World Outcomes

Covid-19 Apr 4, 2021 09:49 PM By Medical Daily Staff Last week Pfizer/BioNTech announced that its coronavirus vaccine will protect people for up to six months after the second dose. But it did lower its effectiveness level from 95% in November 2020, to 91%. That doesn’t surprise Carlos Malvestutto, MD, an infectious disease expert at The Ohio State University Wexner Medical Center. “Real world effectiveness is generally lower than clinical trial efficacy in most cases because clinical trial participants are a selected population of motivated individuals,” he explained. Dr. Malvestutto took the time to answer a few questions for Medical Daily. Q. Why would the results of a real-world study be so far off from those in a controlled trial, in which 10s of thousands of people were participating?

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.